The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial

• DOI: 10.1016/j.jinf.2021.12.033
• Publication Date: 2021-12-25T14:24:43Z
• Authors: Ji-Young Min; Agnes Mwakingwe-O...; Megan Riley; Lifeter Yenwo Molo; Jyoti Soni; Ginette Girard; Jasur Danier
• Keywords: Pneumococcal Conjugate Vaccine

Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus. Adults at increased risk HZ (due to immunocompromising conditions or older age) are also pneumococcal disease, both which preventable by vaccination. We evaluated simultaneous versus sequential administration the adjuvanted recombinant vaccine (RZV) and 13-valent conjugate (PCV13) in adults aged ≥50 years.In this phase IIIB multinational trial (NCT03439657), participants were randomized 1:1 receive either first RZV dose PCV13 simultaneously followed second two months later (Co-Ad, N = 449), two-month intervals, PCV13, dose, sequentially (Control, 463). Objectives demonstrate that immune responses vaccines non-inferior when co-administered compared evaluate safety their co-administration.The response rate (VRR) Co-Ad group was 99.1% (95% confidence interval [CI]: 97.6-99.7), meeting VRR success criterion. Non-inferiority criteria for Control met anti-glycoprotein E antibodies (adjusted geometric mean concentration Control/Co-Ad ratio 1.07 [95%CI: 0.99-1.16]) all serotypes antibody titer ratios 1.02 0.86-1.22] 1.36 1.07-1.73]). Upon co-administration, frequency solicited local adverse events consistent with known profile each individual vaccine, whereas general within same range as alone.RZV had an acceptable profile. Humoral administration. These suggest may benefit receiving a PCV healthcare visit.